Drug intelligence / Profile preview

pedimitex cream

Development stage: Unknown
Lead developer: gepepharm
Modality: Small Molecules
Administration: Topical

Overview

Pedimitex cream is a topical formulation containing 5% permethrin, developed by gepepharm GmbH for the treatment of scabies infestation caused by *Sarcoptes scabiei*. As a synthetic pyrethroid, permethrin acts by disrupting the sodium channel currents in the nerve cell membranes of arthropods, leading to delayed repolarization, paralysis, and eventual death of the mites and their eggs. The drug has undergone Phase 3 clinical evaluation to assess its local and global tolerability in patients with scabies infestation. The name 'pedimitex cream' appears to be the proprietary formulation name used by gepepharm GmbH for their specific permethrin 5% cream product.

Brand names: Pedimitex cream
Other names: permethrin 5% cream

Targets

NaV (Voltage-gated sodium channels)

Beyond the preview

Go deeper on pedimitex cream.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on pedimitex cream.

Explore the full profile